FORMULATION AND EVALUATION OF FAST DISINTEGRATING LOSARTAN POTASSIUM TABLETS BY FORMAL EXPERIMENTAL DESIGN
Abstract
In the treatment of hypertension fast onset of action is the major concern. The problem of slow onset of action of drugs can be overcome by development of appropriate dosage forms. Fast disintegrating tablets in mouth are best suited and have gained popularity in the oral antihypertensive drug therapy. These are advantageous over other conventional systems in terms of patient compliance, rapid onset of action, accurate dosing, good chemical stability, convenience of self-administration and compactness. Losartan potassium is widely used as an antihypertensive drug, which is a potent drug candidate for developing in to Fast Dissolving Tablets (FDT’s). It has low bioavailability due to first pass metabolism. Hence the main objective of the study was to formulate fast dissolving tablets of Losartan potassium to achieve a better dissolution rate and further improving the bioavailability of the drug. Fast dissolving tablet of Losartan potassium were formulated by using microcrystalline cellulose with different concentration of super disintegrants like sodium starch glycolate and Isabgol Mucilage. All the batches were prepared by direct compression.
API characterization studies were conducted to check the purity of API .The tablets were evaluated for Pre compression parameters and post compression parameters. Before the formulation of the tablets IR spectroscopic studies were also performed to check the compatibility with the excipients.
A 23 full factorial design was applied to investigate the combine effect of 3 formulation variables. Here the concentration of Isabgol mucilage, concentration of Sodium Starch Glycolate and concentration of Microcrystalline Cellulose were taken as independent variable X1, X2 & X3 respectively and their effect of disintegration time is studied as dependent parameter. To represent the data Design Expert software is used.
Downloads
References
2. Staniforth J.N., Aulton M.E. Powder flow In: Alton’s Pharmaceutics. The design and manufacturing of medicines. 3rd ed. Hungary: Harcourt publisher Ltd. ; 2007. P. 175‐79.
3. Ansel H.C., Popovich NG, Allen LV. Pharmaceutical dosage forms and drug delivery system. 8th ed. New Delhi: B. I. Waverly Pvt. Ltd.; 1995. p.189‐94, 235‐36.
4. Martin A. Diffusion and Dissolution. In: Physical pharmacy. 3rd ed. Philadelphia: Lea and Febiger; 1983.p.399‐444.
5. Pahwa R, Piplani M, Garg VK, Rao R, Lamba H.S. Formulation and Evaluation of Orally Disintegrating Tablets. Comparison of Natural and Synthetic Superdisintegrants. Scholars Research Library Der Pharmacia Lettre. 2011; 3(2): 407-18.
6. Bhowmik D, Chiranjib.B, jaiswal J, Dubey V, Chandira M. Fast dissolving tablet. A review on revolution of novel drug delivery system and new market opportunities. der pharmacia let 2009;1(2):262-76
7. V. N. Deshmukh. Mouth Dissolving Drug Delivery System: A Review. Int J PharmTech Res 2012;4(1):412-21
8. Ashish P, Harsoliya M.S., Pathan J.K., Shruti S. A Review. Formulation of Mouth Dissolving tablet. Int J Pharm Clin Sci. 2011; 1(1): 1-8.
9. Kaur T, Gill B, Kumar S, Gupta G.D. Mouth dissolving tablets. A Novel approach to drug delivery. Int J Pharm Res. 2011;3(1):1-7.
10. Sagar A.K., Chaudhari P.S., Oswal R.J, Kshirsagar S.S, Antre R.V., Chorage T.V. Mouth dissolving tablets. an innovative technology. Int J App Bio and Pharma Sci. 2011;1(2):496-503.
11. Khan T, Nazim S, Shaikh S, Shaikh A, Khairnar A, Ahmed A. An Approach for rapid disintegrating tablet: A review. Int J Pharma Res Dev. 2011;3(3):170 – 183.
12. Bhatt DA, Rane SI. Qbd approach to analytical RP-HPLC method development and its validation. Int J Pharm Pharm Sci. 2011; 3(1):179-187
13. Example QbD IR Tablet Module 3 Quality 3.2.P.2 Pharmaceutical Development [Internet]. FDA; 2012 Apr [cited 2014 April 27]. Available from:
http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/.
14. Somma R. Understanding Challenges to Quality
by Design Using Quality by Design (QbD) in Designing Efficient, FDA Compliant Pharmaceutical manufacturing processes and facilities. [Internet]. FDA; 2009 Dec [cited 2014 April 27]. Available from:
http://www.pharmaqbd.com/wp-content/uploads /2011/05/Understanding-Challenges-to-Quality-by-Design.pdf
15. Belle GV, Fisher LD, Heagerty PJ, Lumley T. Biostatistics: A Methodology for the Health Sciences. Second Edition. New Jersey: A John Wiley & Sons, Inc., Publication; 2004.
16. Hinkelmann K, Kempthorne O. Design and Analysis of Experiments. Advanced Experimental Design. Volume 2. New Jersey: A John Wiley & Sons, Inc., Publication; 2005.
17. Myers JL, Well AD. Research Design and Statistical Analysis. Second Edition. New Jersey, London: Lawrence Erlbaum Associates Publishers; 2003.
18. Armstrong NA. Pharmaceutical Experimental Design and Interpretation. Second Edition. London: CRC Press Taylor & Francis Group; 2006.
19. Q8 Pharmaceutical Development : ICH guidelines. [Internet]. ICH Expert Working Group; 2009 Aug [cited 2014 April 21]. Available from:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q8_R1/Step4/Q8_R2_Guideline.pdf
20. Guidance for Industry. Q9 Quality Risk Management: ICH guidelines. [Internet]. US FDA; 2006 June [cited 2014 April 28]. Available from:
http://www.fda.gov/downloads/Drugs/.../Guidances/ucm073511.pdf
21. Q10 Pharmaceutical Quality System : ICH guidelines. [Internet]. ICH Expert Working Group; 2008 June [cited 2014 April 21]. Available from:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q10/Step4/Q10_Guideline.pdf.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM
